# A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

> **NCT05754853** · PHASE3 · RECRUITING · sponsor: **Shanghai Miracogen Inc.** · enrollment: 290 (estimated)

## Conditions studied

- Advanced or Metastatic Urothelium Cancer

## Interventions

- **DRUG:** MRG002
- **DRUG:** Docetaxel Injection
- **DRUG:** Paclitaxel Injection
- **DRUG:** Gemcitabine Hydrochloride for Injection
- **DRUG:** Pemetrexed Disodium Injection

## Key facts

- **NCT ID:** NCT05754853
- **Lead sponsor:** Shanghai Miracogen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-06
- **Primary completion:** 2025-10
- **Final completion:** 2027-01
- **Target enrollment:** 290 (ESTIMATED)
- **Last updated:** 2023-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05754853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05754853, "A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05754853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*